Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Xenon Pharmaceuticals has a “Moderate Buy” consensus from 17 analysts, with 13 buys, two strong buys, one hold and one sell. The average 12-month price target is $70.27, though several analysts recently lowered their targets.
• CEO Ian Mortimer and CFO Thomas Patrick Kelly purchased roughly $1.68 million of shares combined near $37 per share, signaling management confidence after the stock’s decline.
• Analysts remain focused on azetukalner (XEN1101), Xenon’s lead epilepsy and depression treatment candidate; RBC said safety concerns are unlikely to derail its approval path. However, the company remains loss-making, with an expected full-year loss of about $4.70 per share.

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seventeen analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, thirteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $70.27.

Several research analysts have recently issued reports on XENE shares. Wedbush reduced their price objective on Xenon Pharmaceuticals from $71.00 to $55.00 and set an "outperform" rating for the company in a research note on Friday, September 18th. Robert W. Baird cut their price target on shares of Xenon Pharmaceuticals from $97.00 to $90.00 and set an "outperform" rating for the company in a report on Friday, September 18th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $46.00 target price (down from $90.00) on shares of Xenon Pharmaceuticals in a report on Friday, September 18th. Royal Bank Of Canada dropped their price objective on shares of Xenon Pharmaceuticals from $81.00 to $70.00 and set an "outperform" rating for the company in a research note on Friday, September 18th. Finally, HC Wainwright restated a "buy" rating on shares of Xenon Pharmaceuticals in a research report on Friday, September 18th.

Key Headlines Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: CEO Ian Mortimer purchased 30,000 shares for approximately $1.12 million, while CFO Thomas Patrick Kelly bought 15,000 shares for about $559,800. The combined purchases, made near $37 per share, may reassure investors that senior management views the recent weakness as an attractive entry point. Insider Buying: Xenon Pharmaceuticals CFO Buys $559,800 in Stock
• Positive Sentiment: RBC said safety issues are unlikely to derail the approval path for azetukalner (XEN1101), Xenon’s lead investigational treatment for epilepsy and major depressive disorder. This reduces concern that safety questions could materially delay a key development catalyst. Xenon’s AZK Approval Path Unlikely to Be Hurt by Safety Issues
• Neutral Sentiment: Xenon granted eight newly hired, non-officer employees 17,850 stock options and 10,500 restricted share units under Nasdaq’s inducement-grant exemption. The awards support recruitment but could modestly increase future share dilution. Xenon Pharmaceuticals Reports Inducement Grants
• Negative Sentiment: Although analysts maintain a broadly positive consensus, recent target-price reductions—including Deutsche Bank’s cut to $46 from $90—highlight continuing concerns about valuation, execution and the path to commercialization. Xenon remains loss-making, with analysts expecting a full-year loss of approximately $4.70 per share.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $38.02 on Friday. The company has a market cap of $3.68 billion, a PE ratio of -8.02 and a beta of 0.60. The firm's 50 day moving average price is $56.32 and its 200-day moving average price is $57.02. Xenon Pharmaceuticals has a 52-week low of $36.07 and a 52-week high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.16) by $0.05. During the same quarter in the prior year, the firm earned ($1.07) earnings per share. On average, analysts forecast that Xenon Pharmaceuticals will post -4.7 earnings per share for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer bought 30,000 shares of the firm's stock in a transaction on Wednesday, September 30th. The shares were bought at an average price of $37.38 per share, with a total value of $1,121,400.00. Following the completion of the transaction, the chief executive officer directly owned 49,923 shares of the company's stock, valued at $1,866,121.74. This represents a 150.58% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher Kenney sold 7,068 shares of the business's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $60.25, for a total transaction of $425,847.00. Following the completion of the sale, the insider directly owned 2 shares in the company, valued at $120.50. This trade represents a 99.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.91% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC acquired a new position in shares of Xenon Pharmaceuticals during the second quarter worth $6,813,000. BlackRock Inc. acquired a new stake in shares of Xenon Pharmaceuticals in the second quarter valued at approximately $454,057,000. Siren L.L.C. grew its position in Xenon Pharmaceuticals by 62.2% during the 1st quarter. Siren L.L.C. now owns 1,318,564 shares of the biopharmaceutical company's stock worth $76,674,000 after purchasing an additional 505,803 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Xenon Pharmaceuticals by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 396,138 shares of the biopharmaceutical company's stock valued at $23,035,000 after purchasing an additional 8,980 shares during the period. Finally, Nicholas Investment Partners LP lifted its holdings in shares of Xenon Pharmaceuticals by 104.0% in the 4th quarter. Nicholas Investment Partners LP now owns 242,989 shares of the biopharmaceutical company's stock valued at $10,891,000 after buying an additional 123,891 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses research in ion channels and neuronal signaling to identify potential treatments for conditions with significant unmet medical needs.

Xenon's lead investigational medicine is azetukalner, also known as XEN1101, a selective potassium channel opener being evaluated for epilepsy and major depressive disorder. The company is also advancing additional programs aimed at genetically defined epilepsies and other disorders of the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.